Calmark Sweden AB logo

CALMA B BTU - Calmark Sweden AB News Story

SEK50 0.0  0.0%

Last Trade - 03/01/20

Sector
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 1786

BRIEF-Calmark Comments On The Effects From COVID-19

Thu 26th March, 2020 1:01pm
March 26 (Reuters) - Calmark Sweden AB  CALMAb.TE :
    * CALMARK COMMENTS ON THE EFFECTS FROM COVID-19 AND
ANNOUNCES
UPDATED TIMETABLE FOR CLINICAL TRIAL AT SÖDERSJUKHUSET
    * UP UNTIL NOW, CALMARK'S DEVELOPMENT PROJECT HAS NOT BEEN
NEGATIVELY IMPACTED BY COVID-19 OUTBREAK
    * WORK IS PROGRESSING AT BEST POSSIBLE PACE
    * IT IS DIFFICULT TO ASSESS TODAY HOW REPRIORITIZATIONS AND
REORGANIZATIONS WILL AFFECT COMPANY AND STUDY
    * AT PRESENT, IT IS DIFFICULT TO ASSESS CONSEQUENCES OF
COVID-19
FOR COMPANY, BOTH WITH REGARD TO OUTBREAK ITSELF AND DECISIONS
THAT FOLLOW IN ITS WAKE
    * CALMARK'S LIQUIDITY IS ABUNDANT FOR TIME BEING THANKS TO
DIRECTED RIGHTS ISSUE WHICH WAS CARRIED OUT IN DECEMBER 2019
    * TEMPORARY MODIFICATIONS MADE TO COMPANY'S SALES PROCESS
MAY
AFFECT PACE OF MARKET LAUNCH

Source text for Eikon:  ID:nWkr1NYh97 
Further company coverage:  CALMAb.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.